Authors:

Fei Teng¹, Huanhuan Guo¹, Di Sun¹, Xinlai Yao¹, Lei Shi¹ , Yi Gu¹, Chuan Qi¹, Lin Shen², Xueming Qian¹ 

¹Suzhou Transcenta Therapeutics Co., Limited, Suzhou, China, ²Peking University Cancer Hospital, Beijing, China

Background:

TST001 (Osemitamab) is a high affinity humanized, ADCC enhanced antibody targeting CLDN18.2. It specifically binds to the extracellular domains of CLDN18.2 and eliminates tumor cells by ADCC and CDC. 

Promising efficacy of TST001 monotherapy in late line G/GEJ cancer patients or plus CAPOX with or without nivolumab as first-line treatment has been observed and reported. 

TST003 is a novel humanized antibody targeting Gremlin-1, a member of TGFb superfamily. Gremlin1 promotes epithelial-mesenchymal transition (EMT) and cancer cell proliferation by binding to BMPs and blocking its biological activities. Here we report preclinical anti-tumor activities of TST001 monotherapy or combined with TST003 in pancreatic cancer models and TST001 monotherapy in pancreatic cancer patients.

Conclusions:

TST001 displayed significant anti-tumor activity in preclinical pancreatic cancer models and higher efficacy when combined with gemcitabine or TST003. 

A pretreated pancreatic cancer patient achieved complete response with TST001 monotherapy. These findings support further investigation of TST001 in CLDN18.2 positive pancreatic cancer patients.